Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

AstraZeneca to invest $1.5 billion in Singapore ADC facility

Published 20/05/2024, 15:56
© Reuters

SINGAPORE - AstraZeneca PLC (LSE/STO/NASDAQ: LON:AZN), a global biopharmaceutical company, has announced plans to invest $1.5 billion in constructing a new manufacturing facility in Singapore dedicated to producing antibody drug conjugates (ADCs). This initiative marks the company's first venture into manufacturing in Singapore and is expected to be fully operational by 2029.

The facility, which will be the first to cover the entire manufacturing process for ADCs at AstraZeneca (NASDAQ:AZN), will be supported by the Singapore Economic Development Board (EDB). ADCs represent a significant advancement in oncology treatment, as they are designed to deliver potent cancer-killing agents directly to cancer cells, minimizing damage to healthy cells.

Png Cheong Boon, Chairman of the EDB, welcomed the investment, noting it as a testament to Singapore's capabilities in biopharmaceutical manufacturing and its potential to create economic opportunities and jobs. The EDB's support underscores the strategic importance of the facility to the region's healthcare and pharmaceutical ecosystem.

Pascal Soriot, CEO of AstraZeneca, emphasized the company's leading portfolio of cancer medicines, including ADCs, which have shown promise in potentially replacing traditional chemotherapy. He expressed enthusiasm for the strategic decision to locate the facility in Singapore, highlighting the country's excellence in complex manufacturing.

The planned greenfield facility will integrate steps such as antibody production, synthesis of the chemotherapy drug and linker, conjugation of the drug-linker to the antibody, and filling of the completed ADC substance. In line with AstraZeneca's commitment to sustainability, the facility is designed to have zero carbon emissions from day one.

AstraZeneca, headquartered in Cambridge, UK, operates in over 100 countries and focuses on prescription medicines in various therapeutic areas, including Oncology and Rare Diseases. The company's decision to build the facility in Singapore aligns with its global expansion strategy and focus on precision medicine.

The construction and design phase of the manufacturing site is slated to begin by the end of 2024.

This article is based on a press release statement from AstraZeneca.

InvestingPro Insights

As AstraZeneca (LSE/STO/NASDAQ: AZN) embarks on a significant expansion with its new manufacturing facility in Singapore, the company's financial health and market performance provide a backdrop to assess this strategic move. With a robust market capitalization of $237.88 billion USD, AstraZeneca stands as a prominent player in the pharmaceuticals industry, as reflected in the InvestingPro Tips. The company's Price/Earnings (P/E) ratio, a key indicator of market expectations about the company's growth and profitability, stands at 37.63. This high earnings multiple suggests that investors may expect AstraZeneca to deliver strong future earnings, aligning with the tip that net income is expected to grow this year.

Furthermore, AstraZeneca has demonstrated a commitment to shareholder returns, maintaining dividend payments for 32 consecutive years, with a current dividend yield of 2.51%. The company's ability to generate cash flows that can sufficiently cover interest payments is another positive signal for investors. Despite trading at a high Price/Book multiple of 6.36, indicating a premium valuation, AstraZeneca's recent performance shows a strong return over the last three months, with a price total return of 20.01%.

For readers looking to delve deeper into AstraZeneca's financial metrics and gain more insights, there are additional InvestingPro Tips available at These tips can help investors make more informed decisions, especially in light of the company's latest venture in Singapore. To access these insights, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking the full suite of analysis and data that InvestingPro offers.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.